What lessons can be learnt from withdrawal of mibefradil from the market?

被引：69

作者：

Po, ALW ^{[1
]}

Zhang, WY ^{[1
]}

机构：

[1] Univ Nottingham, Ctr Evidence Based Pharmacotherapy, Nottingham NG7 2RD, England

来源：

关键词：

D O I：

10.1016/S0140-6736(05)78800-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1829 / 1830

页数：2

共 8 条

[1]

Alderman M, 1997, J HUM HYPERTENS, V11, P331

[2]

BENNETT N, 1998, SUNDAY TELEGRAP 0426, pB5

[3]

*BRIT MED ASS ROYA, 1998, BRIT NAT FORM, V35, P99

[4] Too soon to market [J].

Dent, THS ;

Hawke, S .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7118) :1248-1249

[5] COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].

DIMASI, JA ;

HANSEN, RW ;

GRABOWSKI, HG ;

LASAGNA, L .

[6]

HALL W, 1998, FINANCIAL TIMES 0609, P28

Stanton, AV .

BMJ-BRITISH MEDICAL JOURNAL, 1998, 316 (7143) :1471-1473

[8]

WECHSLER J, 1994, APPL CLIN TRIALS, V3, P18